Post by
mdjbrown on Apr 08, 2024 9:46am
LABS seems like a no brainer heading into 2024
Several catalysts beyond Medipharm’s control that could add a bump to the share price near term
ANVISA approvals
Canadian Federal excise tax cuts
DEA rescheduling announcement
Generic Epidiolex announcements
Any of the current ongoing Trial updates
Increased global Dronbinol orders in first quarter
Reveal of Medipharm’s international partner
Reputable Global Analyst coverage
Q1 improvements to bottom line
Take over announcement
Comment by
subaru1i on Apr 08, 2024 9:51am
Absolutely correct mdj. My only question for the new age romans who think they rule the world at this juncture of accerlating plague and pestilence, why did this happen over 30 years ago? Perhaps the new age romans can consult with the resident senators from Pompei of their old age ancestors.
Comment by
Starkicker on Apr 08, 2024 10:03am
I would expect the mid-May earnings report reveals at least one of the likely/possible points on your list, as well as at least a 30% uptick in revenue from Q1 2023, otherwise it will be a disappointment.
Comment by
QContinuum1 on Apr 08, 2024 12:02pm
Last call, they stated that Brazil approval was expected Q2 (so any time now) and one could also then expect that their Brazil partner will be announced. With the seemingly positive inspection behind them, you have to believe that a Brazil announcement is the next most likely and positive influencer to come.
Comment by
Lvlchange on Apr 09, 2024 9:44am
When does the report come out? Need $$$$
Comment by
Starkicker on Apr 09, 2024 10:02am
Q1 2024 will be mid-May as per MDJ's post a few weeks ago. Q2 mid August and Q3 mid November. Q4 and annual mid March.